The proposed study will consist of a 5-week double-blind cross-over study trial of tolcapone
in 20 people (ages 18-65). The study will be divided into an initial 2 week phase and a
second 2 week phase, with one of the 2 week phases consisting of active treatment with
tolcapone, and the other 2 week phase consisting of inactive placebo treatment. There will be
a one-week wash-out phase between the 2-week treatment phases. Participants will be
randomized to receive either tolcapone or placebo during the first 2 week phase on a 1:1
basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.